PV-001-DV / PrimeVax - LARVOL DELTA

Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses. (PubMed, J Transl Med) - "The direct in vitro tumor-killing and immune-mediated tumor cytotoxicity facilitated by PV001-DV contributes support of its upcoming clinical evaluation in patients with advanced melanoma who have failed prior therapy."

IO biomarker • Journal • Tumor cell • Breast Cancer • Dengue Fever • Immune Modulation • Infectious Disease • Melanoma • Oncology • Solid Tumor • PD-L1

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • BRAF • PD-L1

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Dengue Fever • Melanoma • Oncology • Solid Tumor • PD-L1

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Aug 2023

Combination therapy • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Combination therapy • Trial completion date • Trial primary completion date • Dengue Fever • Melanoma • Oncology • Solid Tumor • PD-L1

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Combination therapy • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor • BRAF • PD-L1